Swiss National Bank
AVIR icon

Swiss National Bank’s Atea Pharmaceuticals AVIR Stock Holding History

Swiss National Bank’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-161,800
Closed -$542K – 2610
2023
Q1 		$542K Sell
161,800
-19,200
-11% -$77.9K ﹤0.01% 2504
2022
Q4 		$871K Buy
181,000
+4,800
+3% +$24.3K ﹤0.01% 2411
2022
Q3 		$1M Hold
176,200
– – ﹤0.01% 2338
2022
Q2 		$1.25M Buy
176,200
+139,700
+383% +$954K ﹤0.01% 2233
2022
Q1 		$264K Hold
36,500
– – ﹤0.01% 2666
2021
Q4 		$326K Hold
36,500
– – ﹤0.01% 2712
2021
Q3 		$1.28M Hold
36,500
– – ﹤0.01% 2317
2021
Q2 		$784K Buy
+36,500
New +$1.1M ﹤0.01% 2551

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Swiss National Bank's AVIR Position: Q2 2023 in Review

Swiss National Bank sold out of Atea Pharmaceuticals (AVIR) in Q2 2023, closing a stake of 161,800 shares — an estimated $542K sold.

Swiss National Bank first reported a position in AVIR in Q2 2021 and held it in 8 quarters. The position peaked at $1.28M in Q3 2021. 133 funds tracked by Wall St. Rank hold AVIR as of Q2 2023.

  • Swiss National Bank reported no remaining Atea Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Swiss National Bank sold 161,800 Atea Pharmaceuticals shares in Q2 2023, an estimated $542K.
  • Swiss National Bank first reported a position in Atea Pharmaceuticals in Q2 2021 and held it in 8 quarters.
  • Swiss National Bank's Atea Pharmaceuticals position peaked at $1.28M in Q3 2021.
  • 133 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2023.

Based on Swiss National Bank's 13F filing for Q2 2023, filed 9 Aug 2023.